• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/1/24 12:31:03 PM ET
    $ADAG
    $AEON
    $AKAN
    $BCLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Sunshine Biopharma (NASDAQ:SBFM) stock rose 86.3% to $0.11 during Monday's regular session. The company's market cap stands at $11.2 million.
    • Xilio Therapeutics (NASDAQ:XLO) stock rose 25.93% to $1.36. The market value of their outstanding shares is at $37.4 million.
    • Akanda (NASDAQ:AKAN) shares moved upwards by 24.35% to $0.14. The company's market cap stands at $1.2 million.
    • Mesoblast (NASDAQ:MESO) shares moved upwards by 20.95% to $6.06. The company's market cap stands at $614.9 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares increased by 18.29% to $0.67. The market value of their outstanding shares is at $32.7 million. The company's, Q4 earnings came out today.
    • Adagene (NASDAQ:ADAG) stock moved upwards by 18.21% to $3.31. The company's market cap stands at $146.0 million.

    Losers

    • Eiger BioPharmaceuticals (NASDAQ:EIGR) stock fell 67.8% to $1.61 during Monday's regular session. The market value of their outstanding shares is at $2.3 million.
    • Disc Medicine (NASDAQ:IRON) stock fell 55.98% to $27.41. The company's market cap stands at $676.5 million.
    • AEON Biopharma (AMEX:AEON) shares decreased by 40.74% to $6.88. The market value of their outstanding shares is at $255.4 million. The company's, Q4 earnings came out yesterday.
    • Biora Therapeutics (NASDAQ:BIOR) stock decreased by 30.92% to $0.76. The company's market cap stands at $20.6 million. As per the press release, Q4 earnings came out 4 days ago.
    • Sharecare (NASDAQ:SHCR) stock declined by 29.44% to $0.54. The company's market cap stands at $191.4 million. As per the press release, Q4 earnings came out 2 days ago.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock fell 28.71% to $0.41. The market value of their outstanding shares is at $4.5 million. The company's, Q4 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $AEON
    $AKAN
    $BCLI

    CompanyDatePrice TargetRatingAnalyst
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    Disc Medicine Inc.
    $IRON
    11/3/2025$125.00Buy
    Stifel
    Xilio Therapeutics Inc.
    $XLO
    8/6/2025$2.00Outperform
    Leerink Partners
    Adagene Inc.
    $ADAG
    8/6/2025$7.00Outperform
    Leerink Partners
    Disc Medicine Inc.
    $IRON
    7/21/2025$86.00Buy
    Truist
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Disc Medicine Inc.
    $IRON
    7/3/2025$85.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    $AEON
    $AKAN
    $BCLI
    SEC Filings

    View All

    AEON Biopharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AEON Biopharma, Inc. (0001837607) (Filer)

    3/9/26 4:05:20 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/9/26 4:05:28 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    3/9/26 8:00:33 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO, CSO, and Corp Secretary Wilson Alexander Blair was granted 2,179,372 shares, increasing direct ownership by 59,988% to 2,183,005 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:07:56 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRINCIPAL ACCOUNTING OFFICER Sy Jennifer was granted 1,500,925 shares, increasing direct ownership by 597,978% to 1,501,176 units (SEC Form 4)

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    3/5/26 6:06:25 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adagene with a new price target

    Guggenheim initiated coverage of Adagene with a rating of Buy and set a new price target of $9.00

    11/24/25 8:15:55 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Disc Medicine with a new price target

    Stifel resumed coverage of Disc Medicine with a rating of Buy and set a new price target of $125.00

    11/3/25 9:08:29 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

    IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory protein

    3/5/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Leadership Updates

    Live Leadership Updates

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

    WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company's Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies. "As we move towards commercialization, we have meaningfully increased hiring to support these efforts and Lisa will play a central role in building a strong, scal

    1/12/26 4:30:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Financials

    Live finance-specific insights

    View All

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

    – FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE

    11/14/25 8:30:00 AM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $AEON
    $AKAN
    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care